Eren, O.O. | Ozturk, M.A. | Sonmez, O.U. | Oyan, B.
Article | 2016 | American Journal of Therapeutics23 ( 6 )
Gastric cancer is still one of the cancers with highest mortality. Most patients present with advancedstage disease. Palliative chemotherapy is usually the only treatment option for patients with advanced gastric cancer (AGC). Maintenance chemotherapy is an evolving concept in medical oncology. Maintenance chemotherapy can be administered with the same drug(s) in the initial regimen or with an alternative agent. In this article, we report our experience with capecitabine as a maintenance agent for patients with AGC. No treatment-related death was observed due to use of capecitabine. Median progression-free survival was 10.4 months, . . .and median overall survival was 19.7 months. Activity and toxicity profile of capecitabine seems favorable as a maintenance agent in AGC. We believe that capecitabine deserves further trials as a maintenance agent for patients with AGC. Copyright © 2015 Wolters Kluwer Health, Inc